SUZHOU, China – Nov. 1, 2019 – Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell-based therapies and products for various indications, including osteoarthritis, stroke, spinal cord injury and cancer, today announced that they have signed a cooperation agreement with Guanggu Nanda International Health Industry Park in Wuhan, China.

A groundbreaking ceremony, attended by municipal and district officials, was held on October 29, 2019 to commence the development of the health industry park, as well as a signing ceremony between Re-Stem Biotechnology Co., Ltd and Guanggu Nanda International Health Industry Park to build a first-class biotechnology research center and a medical rehabilitation center within the park. The International Health Industry Park aims to integrate cellular medicine research, manufacturing and clinical application, in order to benefit a large number of patients.

Pictured: Signing Ceremony of Guanggu Nanda International Health Industry Park attended by Re-Stem’s COO, Judyanna Chen, Wuhan municipal leader, Director Changchun Dan; Mayor Xiexin Chen; Jiangxia District Leader, Secretary of Commission Qinghua Wang; Chairman of the People’s Government Li Zhang; Chairman of the Standing Committee of National People’s Congress Jiashun Tu; Chairman of Committee Xiaolin Jiang; investment funds representative Chairman Tao Yang; General Manager Wei Wang and Chairman Dongling He.

“We are honored to be invited to add our expertise and resources to this new bio-pharmaceutical zone in order to contribute to bringing safe and effective therapies to the patients in Hubei Province and central China,” commented Benno Jiao, CEO of the Company. “Once operational, this research and development lab will add to our growing presence in China, supporting our platform of health services and biotech therapies.”

About Guanggu Nanda International Health Industry Park
Wuhan’s Jiangxia District has formed a health-centered industrial cluster of bio-pharmaceutical, diagnostic equipment, and drug manufacturers. The planned Guanggu Health Industrial Park will cover 98.1 square kilometers. The park will focus on the research and development of cutting-edge technologies in the fields of life and health while incubating key healthcare enterprises. The Health Industry Park is positioned as a “production-research interaction” space, which integrates R&D and manufacturing activities.

About Re-Stem Biotech
Re-Stem Biotech (Re-Stem) is a biotechnology firm engaged in the research and development of cell-based therapies and products. Backed by state of the art GMP facilities and an international team of world-leading scientists, doctors and management team, Re-Stem currently has a robust technology platform including three profitable therapies on the market and eight other therapies and products in the pipeline. Incorporated and headquartered in 2012 in Suzhou, China, Re-Stem is focused on the large and aging population of China. It also operates clinics and research and development laboratories in Shenzhen, Beijing, Kunming and Ganzhou. For more information visit Re-Stem Biotech website: https://www.restembio.com/

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements are inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement objective, plans and strategies for future operations. Forward-looking information may be identified by terms such as “will,” “may,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although Re-Stem believes the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that future results, performance or achievements will be obtained. Re-Stem does not have any obligation to update these forward-looking statements other than as required by law.

Contact
Judyanna Chen
Re-Stem Biotech
judyanna@restembiotech.com